UK TEL: +44 (0) 1234 780020 | USA TEL: +1 888 381 6870
Chronic respiratory diseases affect nearly 550 million people worldwide. Although these conditions are incurable, treatment is available to manage symptoms. Rapid diagnostic tests are crucial in the early detection of an exacerbation, thereby limiting the potential of unfavourable health consequences and improving the patient’s quality of life.
By the time symptoms appear, there is usually already significant lung damage. Respiratory infections further inflame the lungs, compromising breathing and causing further damage to lung tissue.
If these exacerbations can be predicted before the symptoms appear, they can be dealt with earlier, limiting their effect and the potential consequences. Being able to determine whether the inflammation is eosinophil or neutrophil-based can help to determine whether steroids or antibiotics are the best therapy.
Global Access Diagnostics (GADx) is currently developing rapid diagnostic tests for Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). Early detection of exacerbation will enable health professionals and patients to determine whether the inflammation is eosinophil- or neutrophil-based; therefore, decide whether steroids or antibiotics are the best therapy.
It is a rapid test for urine, to detect markers indicating exacerbation of the disease before the symptoms develop.
It is a rapid test of whole blood which can determine if a COPD exacerbation is eosinophilic or neutrophilic to guide either steroid or antibiotic treatment.
It is a rapid test of urine to detect an impending exacerbation of cystic fibrosis before symptoms develop.
*Products in development, not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.
If your company has an existing product or service that helps people manage their chronic respiratory conditions, our products could be a great companion diagnostic for you and help your customers manage their health better.
Our survey of key opinion leaders and healthcare providers showed strong support for an easy to use tool to empower patients to better manage their COPD, resulting in fewer emergency room visits and better health outcomes for your patients.
Our product is designed to put the knowledge and power about your condition into the hands of the person who knows you best: you.
If you see a product that meets your goals to improve the health of your customers, just contact us using the form below.
Whether it is a product in our development phase or a new product idea, we will help you explore options and outline how we can serve you best.
We are flexible in meeting your needs, whether its though licensing, direct sales, a distribution or a development partnership, we can suit your business needs in a seamless process from start to finish.
Get in touch to find out how we can help meet your rapid, point-of-care diagnostics needs.
Mologic Ltd trading as Global Access Diagnostics. Company registered in England and Wales .Company Registration No. 4784437 | All Rights Reserved